COINCIDENT ACUTE MYELOGENOUS LEUKEMIA AND ISCHEMIC-HEART-DISEASE - USE OF THE CARDIOPROTECTANT DEXRAZOXANE DURING INDUCTION CHEMOTHERAPY

Treatment of acute myelogenous leukemia is challenging in the setting of ischemic heart disease because anthracycline and anthracenedione dr ugs used in induction chemotherapy may potentiate myocardial dysfuncti on, We have managed two patients with coincident acute myelogenous leu kemia and ischemic heart disease with the cardioprotectant drug dexraz oxane (ICRF-187), administered before each dose of mitoxantrone or ida rubicin. Both patients tolerated their induction chemotherapy, develop ed marrow hypoplasia from chemotherapy, and achieved clinical remissio n, Dexrazoxane may have a role as a cardioprotectant in the treatment of select patients with acute myelogenous leukemia, (C) 1998 Wiley-Lis s, Inc.